Literature DB >> 16809806

Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects.

Robert J Straka1, R Todd Burkhardt, Nicholas P Lang, Kelly Z Hadsall, Michael Y Tsai.   

Abstract

Polymorphisms of N-acetyltransferase 2 (NAT2) acetylation may influence drug toxicities and efficacy and are associated with a differential susceptibility to select cancers. Acetylation phenotype may have clinical implications. The purposes of this study were to determine the genetic basis of an apparent predominance of slow acetylation phenotype and to assess concordance with genotype in a population of Hmong residing in Minnesota. Urine and DNA obtained from unrelated Hmong 18 to 65 years of age were used to determine phenotype from caffeine metabolites, whereas direct nucleotide sequencing of the NAT2 coding region, followed by cloning, identified all known allelic variants. From 61 subjects (27 men, 30 +/- 11 years), analysis of 50 urine-DNA pairs identified 46 (92%) slow acetylators and 4 (8%) rapid acetylators by phenotype. Genotypic analysis inferred 5 (10%) slow acetylators and 45 (90%) rapid acetylators. There is 86% discordance between phenotype and genotype. A predominance of NAT2 slow acetylation phenotype in the Hmong is confirmed, and a significant discordance between NAT2 phenotype and genotype is identified. In this population, slow acetylation phenotype determined by a metabolic probe would not have been predicted by genotype alone. Environmental, genetic, or phenotypic anomalies that may contribute to this discordance should be considered and evaluated in future studies within this unique population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809806     DOI: 10.1177/0091270006288955

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Leaves imitate trees: Minnesota Hmong concepts of heredity and applications to genomics research.

Authors:  Kathleen A Culhane-Pera; MaiKia Moua; Pachia Vue; Kang Xiaaj; May Xia Lo; Robert J Straka
Journal:  J Community Genet       Date:  2016-11-07

2.  N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians.

Authors:  Olayinka A Kotila; Olufunmilayo I Fawole; Olufunmilayo I Olopade; Adejumoke I Ayede; Adeyinka G Falusi; Chinedum P Babalola
Journal:  Pharmacogenet Genomics       Date:  2019-07       Impact factor: 2.089

3.  Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature.

Authors:  Rika Yuliwulandari; Qomariyah Sachrowardi; Nao Nishida; Miwa Takasu; Lilian Batubara; Tri Panjiasih Susmiarsih; Jecti Teguh Rochani; Riyani Wikaningrum; Risa Miyashita; Taku Miyagawa; Abdul Salam Mudzakir Sofro; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2007-12-27       Impact factor: 3.172

Review 4.  Genotype-Guided Hydralazine Therapy.

Authors:  Kimberly S Collins; Anthony L J Raviele; Amanda L Elchynski; Alexander M Woodcock; Yang Zhao; Rhonda M Cooper-DeHoff; Michael T Eadon
Journal:  Am J Nephrol       Date:  2020-09-14       Impact factor: 3.754

5.  N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.

Authors:  Eleni Aklillu; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Natasa Djordjevic
Journal:  Eur J Clin Pharmacol       Date:  2018-03-27       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.